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Abstract
Cirrhosis is a serious and life-threatening condition which imposes a significant socioeconomic burden on affected individu-
als and healthcare systems. Cirrhosis can result in portal hypertension, which may lead to major complications, including 
acute variceal bleeding and hepatorenal syndrome. Without prompt treatment, these complications may be life-threatening. 
Over the past 2 decades, new treatment modalities and treatment strategies have been introduced, which have improved 
patients’ prognosis, but the initial management of these severe complications continues to present a challenge. The present 
recommendations aim to increase clinicians’ knowledge on the importance of early diagnosis and treatment, and to provide 
evidence-based management strategies to potentially, further improve patient outcomes. Special attention was given to 
the role of terlipressin. A comprehensive non-systematic literature search was undertaken to evaluate the evidence for the 
diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis. Recom-
mendations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with 
cirrhosis have been developed based on the best available evidence and the expert opinion of the consensus panel following 
a comprehensive review of the available clinical data. Prompt identification and timely treatment of acute variceal bleeding 
and hepatorenal syndrome are essential to reduce the burden.
Keywords Acute variceal bleeding · Acute kidney injury · Hepatorenal syndrome · Cirrhosis · Terlipressin · Vasoactive 
drugs
Introduction
Cirrhosis is a serious and life-threatening condition which 
imposes a significant socioeconomic burden on affected 
individuals and healthcare systems worldwide [1, 2]. 
According to a population-based study undertaken in the 
USA, cirrhosis affects over 633,000 adults each year [3] and 
represents the sixth most common cause of death due to 
non-communicable diseases worldwide [4]. In Europe, cir-
rhosis is responsible for 170,000 deaths each year, with wide 
variations between countries [5]. Many cases may be undi-
agnosed, and more than half are potentially preventable [3].
Cirrhosis can result in portal hypertension, which may 
lead to major complications including bleeding gastroe-
sophageal varices and hepatorenal syndrome (HRS), a severe 
form of acute kidney injury (AKI) that usually presents in 
patients with decompensated liver cirrhosis. Esophageal 
varices are present in 30–70% of patients with cirrhosis at 
the time of diagnosis and tend to increase in size in a linear 
fashion [6, 7]. Approximately 4–30% of patients with small 
varices will develop large varices each year and are at risk 
of bleeding [6]. Gastric varices are less common than esoph-
ageal varices, occurring in 5–33% of patients with portal 
hypertension [6], but bleeding tends to be more severe, with 
a reported mortality of approximately 45% [8]. In addition, a 
high proportion of patients with gastric varices rebleed after 
spontaneous hemostasis [9].
Acute variceal bleeding can be fatal and remains a major 
public health problem. In the early 1980s, in-house mortality 
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after variceal hemorrhage was around 40% [10]; however, 
in recent years, in-hospital mortality has fallen steadily to 
10–20%, due to new knowledge on the pathophysiology of 
acute variceal bleeding and advances in therapy [11–13]. 
Although mortality has decreased, bleeding esophageal 
varices (BEV) still remain of significant clinical importance. 
The risk of rebleeding, which is most likely to occur within 
6 weeks of the original episode, remains appreciably high 
[14]. In a nationwide audit undertaken in the UK, mortality 
in those patients who suffered from rebleeding was more 
than fivefold (39 vs. 7%) greater than those patients who 
did not rebleed [14].
HRS is a potentially reversible form of AKI that usu-
ally presents in patients with decompensated liver cirrhosis. 
Between 20 and 50% of hospitalized patients with cirrhosis 
have AKI [15]. HRS is classified into two types based on 
the clinical course, with type 1 HRS being the predominant 
type [16]. Type 1 HRS is defined by a rapidly progressive 
reduction of renal function in less than 2 weeks, while type 
2 HRS is a less progressive, moderate course of renal failure 
characterized by a serum creatinine (sCr) level of > 1.5 mg/
dL (> 133 μmol/L) and is usually accompanied by refrac-
tory ascites [17, 18]. In type 1 HRS, a precipitating factor 
frequently is identified, whereas type 2 HRS arises spontane-
ously [18]. The prognosis of patients with HRS is poor, with 
a reported median survival after diagnosis of only 1.7 weeks 
[19]. Evidence suggests, however, that HRS is potentially 
reversible if hemodynamic derangements are corrected in a 
timely fashion [20].
There have been significant advances in the understand-
ing and treatment of acute variceal bleeding and HRS in 
patients with cirrhosis, and improved survival, but the initial 
management of these serious complications continues to pre-
sent a challenge and requires a multidisciplinary approach. 
The purpose of these recommendations is to provide clini-
cians with evidence-based management strategies that will 
potentially, further improve patient outcomes.
Methods
A multidisciplinary, consensus panel, comprising gastroen-
terologists, hepatologists and critical care physicians from 
Asia, Europe and South America, convened at a meeting 
in London, UK, in November 2016 to review the available 
evidence for the diagnosis and initial management of acute 
variceal bleeding and HRS in patients with cirrhosis and 
to develop a set of recommendations. A comprehensive, 
non-systematic search of the relevant literature electroni-
cally indexed in PubMed, EMBASE, the Cochrane Library 
and clinicaltrials.gov was undertaken using the following 
key words: hepatorenal syndrome, cirrhosis, acute kid-
ney injury, varices, vasoactive, terlipressin, vasopressin, 
octreotide, midodrine, noradrenaline. No language limits 
were set on the database searches. Randomized and non-
randomized controlled trials, crossover trials, single-arm 
studies, cohort studies, case–control studies and case series 
were included, as well as published data from registries and 
medical databases. The search results were supplemented by 
manual searching of relevant journals, reference lists in key 
journals and other appropriate documents, as well as expert 
opinion. All recommendations were based on the best avail-
able evidence combined with the authors’ experiences in 
managing acute variceal bleeding and HRS in patients with 
cirrhosis. For each section, recommendations were made 
and evidence levels graded according to the Oxford Cen-
tre for Evidence-Based Medicine Levels of Evidence [21, 
22]: Grade A (consistent level 1 studies [systematic review 
of randomized controlled trials (RCT) and RCT]); Grade B 
(consistent level 2 or 3 studies or extrapolations from level 1 
studies [systematic review of cohort studies, cohort studies, 
and low quality RCT]); Grade C (level 4 studies [systematic 
review of case–control studies, case–control studies and case 
series] or extrapolations from level 2 or 3 studies; Grade D 
(level 5 studies [expert opinion] or troublingly inconsistent 
or inconclusive studies at any level).
Management of Bleeding Gastroesophageal 
Varices
Diagnosis of Varices
Current guidelines recommend that all patients with cir-
rhosis should be screened for the presence of varices at 
the time of diagnosis, with follow-up every 2–3 years for 
compensated patients without varices (depending upon liver 
disease severity) and 1–2 yearly for compensated patients 
with small varices, to evaluate progression of varices and the 
need for prophylactic treatment [12, 23]. During follow-up 
of patients with chronic liver disease, noninvasive methods 
include transient elastography and use of laboratory and 
radiological findings, which are useful for the selection of 
patients for endoscopy [23]. Variceal hemorrhage should be 
suspected when a patient with known cirrhosis or evidence 
of portal hypertension presents with upper gastrointestinal 
hemorrhage [8].
Recommendation
• All patients with suspicion of cirrhosis should be 
screened for the presence of gastroesophageal varices 
(Grade A).
• Noninvasive methods such as elastography are useful to 
select patients with chronic liver disease for endoscopy 
to rule out gastroesophageal varices (Grade C).
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Initial Treatment
Prophylactic measures such as non-selective beta blocker 
(NSBB) use and endoscopic variceal ligation are available 
to prevent initial bleeding [12, 23]. Acute variceal hemor-
rhage is a medical emergency that requires prompt treatment 
and should ideally be managed in an intensive care unit. The 
key goals of treatment are to control the acute hemorrhage, 
prevent early (within 5 days) rebleeding and reduce mor-
tality. The optimal management of acute bleeding requires 
a multifactorial approach. Volume replacement should be 
initiated as soon as possible to restore and maintain hemody-
namic stability [24]. The treatment of acute variceal bleed-
ing includes antibiotic prophylaxis, the use of vasoactive 
drugs and endoscopic treatment.
Antibiotic Prophylaxis
Bacterial infections are common due to gut translocation and 
motility disturbances [6]. Standard practice is to give short-
term (maximum 7 days) antibiotic prophylaxis in any patient 
with cirrhosis and bleeding esophageal varices (BEV) [6, 
23, 24]. In a meta-analysis of 5 trials (534 patients), short-
term (5–10 days) antibiotic prophylaxis was shown to sig-
nificantly increase the mean percentage of patients free of 
infection (32% mean improvement rate, 95% confidence 
interval [CI] 22–42; P < 0.001) and significantly increase 
short-term survival rate (9.1% mean improvement rate, 95% 
CI 2.9–15.3; P = 0.004) [25].
Vasoactive Drugs
After resuscitation, volume replacement and prophylactic 
antibiotics, there are a number of specific treatment options 
available to treat BEV. To date, the best evidence for efficacy 
is vasoactive drugs combined with endoscopic treatment as 
it achieves better control of acute bleeding than endoscopic 
treatment alone [26]. In a meta-analysis of 8 trials involving 
939 patients, combined use of endoscopic and drug therapy 
improved initial control of bleeding (relative risk [RR] 1.12, 
95% CI 1.02–1.23) and 5-day hemostasis (RR 1.28, 95% CI 
1.18–1.39) [26].
A number of vasoactive drugs, including vasopressin, 
terlipressin, somatostatin and octreotide, are available. In a 
meta-analysis of 30 RCTs, the use of intravenously admin-
istered vasoactive drugs was shown to significantly lower 
the risk of all-cause mortality within 7 days (RR 0.74, 95% 
CI 0.57–0.95; P = 0.02) and significantly improve hemosta-
sis (RR 1.21, 95% CI 1.13–1.30; P < 0.001) compared with 
control. Studies comparing different vasoactive drugs did 
not show a difference in efficacy, although the quality of 
evidence was low [27].
Terlipressin is superior to placebo in the control of 
variceal hemorrhage [28–30] (Table 1). In addition, ter-
lipressin has shown to have mortality benefit in placebo-
controlled trials [28, 31] and meta-analysis [32]. Seven 
studies comparing terlipressin to placebo (443 patients) 
were included in the meta-analysis by Ioannou et al. [32]. 
Terlipressin was associated with a statistically significant 
reduction in all-cause mortality compared with placebo 
(RR 0.66, 95% CI 0.49–0.88). Conversely, in comparative 
studies of different vasoactive drugs (terlipressin, somato-
statin and octreotide) no significant differences were found 
among them regarding control of hemorrhage or mortality 
(Table 2) [33–38]. Many of these original studies, however, 
were conducted more than 20 years ago and are limited by 
small sample sizes and study designs.
Safety of Terlipressin
Most studies have shown that vasoactive drugs have a good 
safety profile, although vasopressin can cause an increase in 





d Bleeding episodes (34 patients in total)
Author Study design Drug n Control of bleeding % 
(P value)
Mortality % (P 
value)
Söderlund et al. [28] Randomized, double-blind, placebo-controlled Terlipressin 31 90.3 (< 0.01) 9.7a (0.014)
Placebo 29 58.6 37.9a
Freeman et al. [29] Randomized, double-blind, placebo-controlled Terlipressin 15 60.0 (NS) 20.0a –
Placebo 16 37.0 25.0a
Walker et al. [30] Single center, prospective, randomized, double-
blind, placebo-controlled
Terlipressin 25d 100b (< 0.05) 12.0c (NS)
Placebo 25d 80.0b 32.0c
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peripheral resistance and reduction in cardiac output, heart 
rate and coronary blood flow [23]. Terlipressin has a favora-
ble adverse effect profile and is related to fewer cardiovascu-
lar side effects when compared to vasopressin due to its pref-
erential binding to V1 receptors [39]. Adverse events (AEs) 
are mostly cardiovascular and related to vasoconstriction 
[40]. Side effects include angina pectoris, acute myocardial 
infarction, bradyarrhythmia, peripheral vascular ischemia, 
mesenteric ischemia and systemic arterial hypertension [39]. 
In a meta-analysis by Ioannou et el. [32], there was no sig-
nificant difference between the terlipressin group and any 
of the comparison groups in the number of AEs that caused 
death or withdrawal of medication. Terlipressin should be 
avoided or used with caution in patients with preexisting 
cardiovascular disease and in patients over 70 years of age 
as experience is limited in this patient population.
Patients receiving terlipressin for the treatment of 
BEV may develop hyponatremia, which is usually revers-
ible after terlipressin withdrawal [41, 42]. The most 
likely explanation of terlipressin-induced hyponatremia 
is the agonistic activity on renal V2 vasopressin recep-
tors causing free water retention. The administration 
of hypotonic fluid strongly favors the development of 
acute hyponatremia in this situation. In two of the stud-
ies [41, 42], patients who developed hyponatremia had 
less advanced liver disease and higher baseline serum 
sodium concentration, suggesting that in these patients 
the V2 vasopressin receptors were not yet occupied by 
endogenous vasopressin. This may explain why hypona-
tremia is uncommon during the administration of terlipres-
sin for HRS, a situation which occurs in more advanced 
liver disease. These findings highlight the need for daily 
monitoring of serum sodium levels in patients receiving 
terlipressin for acute gastrointestinal bleeding due to por-
tal hypertension, as is routinely performed in all patients 
with cirrhosis and that in patients with low MELD (Model 
For End-Stage Liver Disease), and normal to near-normal 
baseline serum sodium concentrations, hypotonic fluids 
should be avoided. Whether the administration of albumin 
might counteract this side effect needs to be explored.
NSBBs should be avoided when treating patients with 
active BEV with terlipressin since they can potentially 
induce systemic hypotension [43]. After review of the 
literature, it is recommended that NSBBs are suspended 
in patients with BEV during terlipressin infusion and 
restarted when the terlipressin course is finished.





d During the trial
e Combined with transdermal nitroglycerine
f At 12 h
g Bleeding episodes (72 patients in total)




Feu et al. [35] Multicenter, double-blind, randomized Terlipressin 80 80.0 (NS) 16.3a –
Somatostatin 81 84.0 16.0a
Walker et al. 36] Double-blind, randomized, placebo controlled Terlipressin 53g 90.6 – 20.8b (NS)
Somatostatin 53g 81.1 20.8b
Seo et al. [33] Non-blinded, non-inferiority Terlipressin 261 86.2c (NS) 8.0c (NS)
Somatostatin 259 83.4c 8.9c
Octreotide 260 83.8c 8.8c
Abid et al. [34] Single center, randomized, double-blind, placebo-
controlled, non-inferiority design
Terlipressin 163 96.9 (NS) 5.5d (NS)
Octreotide 161 99.4 4.3d
Pedretti et al. [37] Single center, single-blind, randomized Terlipressine 30 53.3 (NS) 13.3 (NS)
Octreotide 30 76.6 10.0
Silvain et al. [38] Multicenter, randomized Terlipressin 41 59.0f (NS) 0.0f
28.0b
(NS)
Octreotide 46 78.0f 6.0f
22.0b
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Co‑administration of Terlipressin and Somatostatin 
or Octreotide
Kalambokis et al. [44] evaluated the effects of somatosta-
tin, terlipressin and combined treatment with somatostatin 
and terlipressin on portal hemodynamics in a randomized, 
placebo-controlled study of 24 patients with cirrhosis and 
esophageal varices. Combined treatment did not exert an 
additive portal hypotensive effect as compared to terlipres-
sin alone. A previous study by Lin et al. [45] also showed 
a lack of an additive portal hypotensive effect of octreotide 
and terlipressin in patients with cirrhosis.
Rationale for the Early Use of Vasoactive Drugs
A prospective cohort study of 314 patients with cirrhosis 
and esophageal varices (173 [55%] with no previous history 
of variceal bleeding) found that about a quarter of deaths 
occurred very early after bleeding onset, confirming the 
need for rapid specific management [46]. Available evi-
dence suggests that early use of vasoactive drugs improves 
hemostasis before endoscopy [31, 47, 48]. In a prospective, 
randomized study comprising 76 patients with cirrhosis and 
active upper gastrointestinal bleeding, terlipressin combined 
with glyceryl trinitrate administered early (before hospital 
admission) significantly improved the control of bleeding 
(P = 0.034) and reduced mortality at day 15 (P = 0.035) 
and day 42 (P = 0.06) compared with placebo [31]. In a 
double-blind, prospective study involving 205 patients, at 
endoscopy, active bleeding from esophageal varices was less 
frequent (P = 0.012) and the sclerotherapy procedure was 
easier (P = 0.0027) in the somatostatin than in the placebo 
group [47].
Optimal Dosage Regimen of Terlipressin
The current standard practice is to give terlipressin as an 
intravenous injection, initially a 2 mg bolus injection, then 
1–2 mg every 4 or 6 h depending on the bodyweight of the 
patient and their co-morbidities. Escorsell et al. [49] showed 
that the hemodynamic effect of terlipressin on portal pres-
sure lasts no more than 3–4 h, which raises the question as 
to whether continuous infusion may have better efficacy than 
bolus injections. While a continuous infusion is possible, it 
remains unclear whether or not it should be considered in 
clinical practice. A clinical trial comparing the safety and 
efficacy of the two infusion types in patients with BEV is 
currently underway [50]. In another study, Chang et al. [51] 
investigated whether a high-dose terlipressin could control 
acute variceal hemorrhage more effectively than a low-dose 
terlipressin. Complete control of bleeding during 24 h of 
drug infusion was achieved in 53% of patients receiving 
high-dose terlipressin (2 mg) and in 48% of those treated 
with low-dose terlipressin (1 mg). Further randomized stud-
ies are needed to evaluate the effects of low-dose terlipressin.
Current guidelines recommend that vasoactive drug treat-
ment should be maintained for up to 5 days since this is the 
time period in which rebleeding is more frequent [12, 23]. 
Azam et al. [52] investigated whether terlipressin can be 
administered for a shorter period of time to patients with 
BEV. Terlipressin given for 24 h was shown to be as effec-
tive as a 72-h course when used as an adjunctive therapy to 
successful endoscopic variceal band ligation.
Recommendations
• If variceal bleeding is suspected, vasoactive drugs should 
be given before endoscopy (Grade B). Terlipressin is a 
drug of choice and should be started as soon as possible 
when available, and there is no contraindication (Grade 
A).
• The use of continuous infusion of terlipressin in BEV has 
not been established (Grade D).
• Close monitoring is required in patients with cardiovas-
cular comorbidity taking terlipressin, and a lower dose 
should be considered. Serum sodium levels should be 
monitored and the use of hypotonic fluid avoided (Grade 
D).
• There is insufficient evidence of the additional effect of 
co-administration of terlipressin with other vasoactive 
drugs (Grade D).
Endoscopic Therapy
Endoscopy should be scheduled in all patients with upper 
gastrointestinal bleeding. However, the timing is still contro-
versial. There are not enough data to support that endoscopy 
has to be performed within < 12 h. The endoscopic treatment 
of choice is band ligation (EBL) [13, 53]. Erythromycin 
(250 mg IV 30–120 min) before endoscopy in patients with 
variceal bleeding significantly improves endoscopic visibil-
ity and shortens the duration of the index endoscopy [54]. 
Recommended treatment with combined vasoactive drugs 
and endoscopic therapy results in successful 5-day control 
of bleeding in 85–90% of cases [55].
Transjugular Intrahepatic Portosystemic Shunt 
Placement
Studies have shown that transjugular intrahepatic porto-
systemic shunt (TIPS) is an extremely useful technique for 
the treatment of BEV in rescue situations and in high-risk 
patients. In a RCT of 63 high-risk patients with cirrhosis 
and BEV who had been treated with vasoactive drugs plus 
endoscopic therapy, the early use of TIPS was associated 
with significant reductions in treatment failure and mortality. 
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Rebleeding or failure to control bleeding occurred in 14 
patients in the pharmacotherapy-endoscopic band ligation 
(EBL) group compared with 1 patient in the early TIPS 
group (P = 0.001). The 1-year actuarial survival was 61% 
in the pharmacotherapy-EBL group compared with 86% in 
the early TIPS group (P < 0.001) [13]. High-risk patients 
were defined as Child–Pugh Class B patients with persistent 
bleeding at endoscopy and Child–Pugh Class C (score < 14). 
A post-RCT surveillance study confirms these findings in 
clinical practice [53]. Patients treated with early TIPS had 
a much lower incidence of failure to control bleeding or 
rebleeding than patients receiving drugs and endoscopic 
therapy (3 vs. 15; P < 0.001). The same was observed for 
mortality [53]. The value of early TIPS outside high-risk 
patients is currently being investigated.
Recommendations
• Band ligation is the endotherapy of choice (Grade A).
• Pre-endoscopy infusion of erythromycin should be con-
sidered to avoid aspiration pneumonia (Grade B).
• Early TIPS is the treatment of choice in Child–Pugh 
Class B patients with persistent bleeding during endos-
copy and in Child–Pugh Class C (score < 14) patients 
(Grade A).
Cyanoacrylate Injection Therapy
There are still limited data on the use of tissue glue 
cyanoacrylate (N-butyl-2-cyanoacrylate) in the treatment of 
BEV in patients with cirrhosis, although in one prospective 
cohort study of 133 consecutive patients, initial hemostasis 
was achieved in 94.2% of patients with active bleeding (95% 
CI 85.1–98.5). Overall, early recurrent bleeding occurred 
in 5.2% of patients (95% CI 2.3–10.1) [56]. These findings 
are supported by the results of another prospective study of 
63 patients with cirrhosis admitted with an acute episode 
of BEV. Bleeding was controlled in almost 75% of patients 
during the first 5 days after treatment, and 54% of patients 
were free of bleeding at 6 weeks after treatment [57].
Recommendation
• There are limited data on the use of cyanoacrylate injec-
tion therapy in the treatment of BEV in patients with 
cirrhosis (Grade D).
Management of Acute Gastric Variceal Bleeding
The optimal treatment for bleeding gastric varices remains 
unclear as there are few RCTs. General consensus is that 
the initial management is similar to that of BEV, includ-
ing the use of prophylactic antibiotics, careful f luid 
resuscitation with a restrictive transfusion policy and the 
early administration of vasoactive drugs (terlipressin, 
somatostatin or a somatostatin analogue [12, 58]. There 
are limited data on the efficacy of vasoactive drugs in con-
trolling acute gastric variceal bleeding [36], but general 
consensus is that terlipressin can be considered for patients 
with acute gastric variceal bleeding when used alongside 
glue injection of the varices.
Cyanoacrylate has been successfully used in many 
countries and is effective in the management of bleeding 
gastric varices [59–62]. Al-Ali et al. [63] retrospectively 
reviewed 37 patients with portal hypertension secondary 
to liver disease and active bleeding treated with cyanoacr-
ylate. Hemostasis was achieved in 95% of patients. Early 
rebleeding occurred in only 3 patients (8%) during the 
same hospital admission. However, a Cochrane review 
undertaken in 2015 concluded that the comparison of 
cyanoacrylate versus alcohol compounds to treat gastric 
variceal bleeding remains uncertain due to the very low 
quality of the evidence [64].
In treatment failures, TIPS is considered the treatment 
of choice [65, 66]. In a study by Chau et al. [65], 112 
consecutive patients with uncontrolled bleeding required 
emergency TIPS (84 with esophageal varices unresponsive 
to endoscopic therapy and vasoactive drugs and 28 with 
gastric varices unresponsive to vasoactive drugs). Variceal 
bleeding was controlled in all patients after TIPS except 
for one in each group. During a median follow-up period 
of 7 months, 20 in the BEV group (24%) and 8 in the 
gastric varices group (29%) developed clinical rebleed-
ing. Most early rebleeding (within 7 days after TIPS) was 
related to esophageal ulceration secondary to previous 
sclerotherapy. In another study comprising 58 patients 
refractory to sclerotherapy and pharmacological treat-
ment, hemorrhage was controlled following salvage TIPS 
in 90% of patients. Bleeding persisted in 10% of patients 
and recurred in 7% [66]. There is a place for TIPS in the 
prevention of gastric variceal rebleeding; a RCT of TIPS 
versus cyanoacrylate injection concluded that TIPS proved 
more effective than cyanoacrylate in preventing rebleeding 
from gastric varices [67].
Recommendations
• Limited data are available on the efficacy of vasoactive 
drugs in controlling acute gastric variceal bleeding. Ter-
lipressin can be considered when used alongside glue 
injection of the varices (Grade D).
• TIPS should be considered in patients who have uncon-
trolled gastric variceal bleeding refractory to endoscopic 
therapy and vasoactive drugs and for the prevention of 
gastric variceal rebleed (Grade C).




The most widely accepted diagnostic criteria for HRS were 
published by the International Club of Ascites (ICA) in 1996 
[68] and modified in 2007 [17]. In 2015, the ICA proposed a 
new definition for cirrhosis-related AKI and further modifi-
cations of the diagnostic criteria for HRS-related AKI [69]. 
These revisions were needed because the definition of type 
1 HRS did not allow physicians to initiate potentially effec-
tive treatment, specifically vasoactive drugs and albumin, 
until the sCr increased to ≥ 2.5 mg/dL [69]. Studies have 
shown that a higher sCr at the beginning of treatment leads 
to a lower probability of treatment response with terlipressin 
and albumin [70, 71].
The ICA define AKI as the increase in sCr of at least 
0.3 mg/dL (26 μmol/L) within 48 h or a percentage increase 
sCr ≥ 50% from baseline, which is known, or presumed, to 
have occurred within the prior 7 days [69]. Once AKI is 
diagnosed, the stage of AKI should be identified (Table 3).
For patients to be diagnosed with HRS-AKI using these 
criteria, they need first to progress from Stage 1 to Stage 
2 and 3 AKI, when the withdrawal of diuretics is recom-
mended (if they have not been withdrawn already), and 
volume expansion with albumin (1 g/kg) should be admin-
istered for 2 days. If the patient then fails to respond, the 
HRS-AKI criteria should be used to determine whether the 
patient has HRS-AKI or another AKI phenotype [69]. The 
ICA criteria for the diagnosis of HRS-AKI are summarized 
in Table 4. At present, these guidelines do not differentiate 
between type 1 and type 2 HRS, although there are clear 
differences between the two and the management of patients 
differs depending on HRS subtype.
Recommendations
• It is important to make the diagnosis of HRS-AKI or 
identify other known causes of renal failure in cirrhosis 
as early as possible. The diagnosis should be based on the 




The general management of patients with cirrhosis and type 
1 HRS depends on the severity of kidney failure and associ-
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treatment is started early in order to prevent the progression 
of renal failure [72]. The goal of treatment is to improve 
renal function. The administration of vasoactive drugs (ter-
lipressin, noradrenaline and midodrine plus octreotide) in 
combination with albumin is currently considered the treat-
ment of choice. Albumin has been shown to improve circula-
tory function in cirrhosis by expanding central blood volume 
and increasing cardiac output [73]. Among the vasoactive 
drugs, terlipressin is the most widely studied for the treat-
ment of type 1 HRS.
In clinical trials and published meta-analyses [20, 74, 75], 
terlipressin treatment was superior to placebo for achiev-
ing reversal of HRS. Meta-analysis of 12 RCTs enroll-
ing 700 patients with type 1 HRS supports the beneficial 
effect of terlipressin on renal function [20]. Treatment with 
terlipressin in combination with albumin led to HRS reversal 
more frequently than albumin alone or placebo (RR 2.54, 
95% CI 1.51–4.26), although the mortality benefit was less 
clear. Noradrenaline was effective in reversing HRS, but tri-
als were small and non-blinded [20].
Studies have also shown that the administration of ter-
lipressin, together with albumin, is effective in improving 
renal function in patients with cirrhosis and HRS compared 
with albumin administration alone [76–80]. In REVERSE 
[76], a large, phase 3 multicenter, randomized, placebo-
controlled trial, which included 196 patients with cirrhosis 
and type 1 HRS, terlipressin plus albumin was more effec-
tive than placebo plus albumin in improving renal function, 
based on a significant decrease in SCr value from baseline 
to end of treatment (P < 0.001). However, there was no 
significant difference in the incidence of confirmed HRS 
reversal (19.6 vs. 13.1%) or HRS reversal (23.7 vs. 15.2%) 
between the two groups. Further analysis of pooled data 
from REVERSE and OT‐0401, a similarly designed phase 
2 clinical study comprising 308 patients, demonstrated that 
the addition of terlipressin to albumin provides a significant 
benefit in terms of HRS reversal in patients with type 1 HRS 
[77].
Other drugs currently used in the management of type 1 
HRS include noradrenaline and midodrine, alpha-adrenergic 
agonists that lead to constriction of vascular smooth mus-
cle and increase systemic vascular resistance [20]. Their 
effectiveness has been studied in several studies, and data 
suggest that noradrenaline is as effective as terlipressin in 
improving renal function in patients with cirrhosis and HRS 
(Table 5) [81–84]. Midodrine is often used in combination 
with octreotide. Cavallin et al. [85] compared the effective-
ness of terlipressin plus albumin with oral midodrine and 
Table 4  International Club of Ascites diagnostic criteria of HRS type 
of AKI in patients with cirrhosis (HRS-AKI) [69]
a Patients who fulfill these criteria may still have structural damage 
such as tubular damage
Diagnosis of cirrhosis and ascites
Diagnosis of AKI according to ICA-AKI criteria
No response after 2 consecutive days of diuretic withdrawal and 
plasma volume expansion with albumin 1 g per kg of body weight
Absence of shock
No current or recent use of nephrotoxic drugs (non-steroidal anti-
inflammatory drugs, aminoglycosides, iodinated contrast media, 
etc.)
No macroscopic signs of structural kidney  injurya, defined as:
 Absence of proteinuria (> 500 mg/day)
 Absence of microhematuria (> 50 red blood cells per high power 
field)
 Normal findings on renal ultrasonography





d Albumin was administered in combination with these drugs
Author Study design Drugd n Reversal of 




Alessandria et al. [84] Single center, prospective, randomized, non-blinded, pilot Terlipressin 5 80.0 – 80.0a –
Noradrenaline 4 75.0 50.0a
Sharma et al. [83] Single center, open label, pilot, randomized controlled Terlipressin 20 50.0 (NS) 55.0b (NS)
Noradrenaline 20 50.0 55.0b
Singh et al. [82] Single center, prospective, randomized, non-blinded Terlipressin 23 39.1 (NS) 39.1b (NS)
Noradrenaline 23 43.4 47.8b
Goyal et al. [81] Single center, prospective, open label, randomized Terlipressin 20 45.0 (NS) 45.0c –
Noradrenaline 21 47.6 47.6c
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octreotide plus albumin in a randomized trial comprising 49 
patients with cirrhosis and type 1 or 2 HRS. There was a sig-
nificantly higher rate of recovery of renal function in patients 
randomized to the terlipressin plus albumin group than in 
patients randomized to the oral midodrine and octreotide 
plus albumin group (70.4 vs. 28.6%; P = 0.01).
Reporting of AEs in patients with HRS treated with 
vasoactive drugs varies between studies. In a meta-analysis 
by Gifford et al. [20], there were fewer ischemic AEs with 
noradrenaline, although sample sizes were small in pub-
lished studies. In the REVERSE study, the safety profile of 
terlipressin generally was consistent with previous clinical 
studies and included AEs expected with vasoactive drugs. 
The overall AE rate did not differ between the terlipressin 
and placebo groups. Gastrointestinal events, most commonly 
abdominal pain and diarrhea, were the most frequent treat-
ment-related AEs. Ischemic events were more common in 
patients receiving terlipressin, as was expected [76]. Tailor-
ing treatment, such as modifying the dose and the method of 
administration, can help reduce these side effects.
Optimal Dosage Regimen of Terlipressin
Current guidelines recommend that terlipressin 1 mg should 
be given every 4–6 h by intravenous bolus injection, in 
combination with albumin [72]. The aim of treatment is 
to improve renal function by decreasing sCr < 133 μmol/L 
(< 1.5 mg/dL), which indicates complete response [72]. In 
some countries, a lower initial dose of terlipressin is given 
in daily practice (0.5 mg) [16]. This dose has been found to 
be as effective as 1 mg in clinical practice, but benefits from 
fewer side effects.
In a RCT, Cavallin et al. [86] demonstrated that terli-
pressin given by continuous infusion was better tolerated 
than intravenous boluses in the treatment of type 1 HRS 
and presented fewer side effects (35.3 vs. 62.2%; P < 0.025). 
Terlipressin was also effective at doses lower than those 
required for intravenous bolus administration. The rate of 
response to treatment, including both complete and partial 
response, was not significantly different between the two 
groups (76.5 vs. 64.9%).
Recommendations
• Terlipressin can be given as a continuous intravenous 
infusion (Grade B).
• Bolus administration of terlipressin, which was origi-
nally tested and recommended, can also be considered, 
although with more side effects and similar effectiveness 
(Grade A).
• Patients who meet diagnostic criteria of HRS-AKI should 
be given terlipressin 1 mg every 4–6 h by intravenous 
bolus injection, when available and there is no contrain-
dication, in combination with albumin (Grade A). Ter-
lipressin can be administered at a lower initial dose of 
0.5 mg in type 1 HRS (Grade C).
• Terlipressin should be used with caution in patients with 
underlying severe cardiovascular or peripheral arterial 
disease. Patients should be closely monitored for cardio-
vascular or ischemic side effects (Grade A).
Acute on Chronic Liver Failure and Type 1 HRS
Acute on chronic liver failure (ACLF) is a recognized syn-
drome that develops in patients with cirrhosis and is charac-
terized by acute decompensation of cirrhosis, single or mul-
tiple organ failures, severe systemic inflammation and high 
short-term mortality [87]. AKI is one of the defining features 
of ACLF and is important for grading the severity of ACLF 
[88]. ACLF is graded into three stages: ACLF-1 =  single 
renal failure or single non-renal organ failure if associ-
ated with renal dysfunction and/or cerebral dysfunction; 
ACLF-2 = two organ failures; and ACLF-3 = three to six 
organ failures, with increasing 28-day mortality rate [89]. 
In order that appropriate and early management can be initi-
ated, it is important to distinguish between non-HRS-AKI 
and HRS-AKI when reviewing patients with ACLF and AKI 
[88]. Terlipressin infusion provides earlier response (Day 
7: 41.7 vs. 20.0%; P = 0.01), greater HRS reversal (40.0 
vs. 16.7%; P = 0.004) and improved survival (28-day: 48.3 
vs. 20.0%; P = 0.001) compared to noradrenaline in ACLF 
patients with HRS‐AKI [90].
Terlipressin and albumin are effective treatments for type 
1 HRS; however, the effects of ACLF grade on response to 
treatment are not clear [91]. In a recent retrospective analysis 
of four different cohorts of consecutive patients with HRS 
treated with terlipressin and albumin, ACLF grade was the 
largest determinant of response. Of patients with grade 1 
ACLF, 60% responded to treatment; among those with grade 
2 ACLF, 48% responded, and among those with grade 3 
ACLF, 29% responded (P < 0.001 for comparison between 
grades) [91].
Recommendations
• Treatment with terlipressin in patients with ACLF and 
HRS is associated with an improvement in kidney func-
tion and should be started as soon as possible after the 
diagnosis of type 1 HRS. The success depends on the 
grade of ACLF (Grade B).
Type 2 HRS
There is limited evidence for the use of vasoactive drugs 
in patients who have type 2 HRS. Some trials combined 
patients with type 1 and type 2 HRS, but the sample sizes 
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were small. Two studies evaluated the use of terlipressin in 
this patient population [92, 93]. In a randomized study of 
46 patients with cirrhosis and HRS, improvement of renal 
function was more frequent in patients with type 2 HRS 
compared with that of patients with type 1 HRS (67 vs. 35%, 
respectively) treated with terlipressin and albumin, although 
the difference was not statistically significant [92].
Recommendations
• There is limited evidence for the use of terlipressin in 
combination with albumin for patients who have cirrho-
sis and type 2 HRS, although it has been shown to be 
effective in clinical practice (Grade C).
• Further prospective studies are needed to assess the effi-
cacy of terlipressin in patients with cirrhosis and type 2 
HRS (Grade D).
Conclusions
Variceal bleeding and HRS are severe complications of 
cirrhosis associated with significant morbidity and mortal-
ity. Data have shown that early diagnosis and intervention 
improve patients’ prognosis. The primary goals of treatment 
for BEV are to control the acute hemorrhage, prevent early 
rebleeding and reduce mortality. Vasoactive drugs are used 
as initial treatment of BEV before endoscopy. Evidence from 
a multitude of clinical trials and meta-analyses comparing 
different vasoactive drugs suggests near equivalence in effi-
cacy in terms of initial hemostasis. With terlipressin, mor-
tality benefit was observed. In order to further improve the 
tolerability of terlipressin, the use of continuous intravenous 
infusion is currently being explored.
The primary goal of pharmacological therapy in HRS 
is normalization of renal function. The revised ICA HRS-
AKI criteria allow physicians to initiate potentially effective 
treatment, earlier, which might further improve the survival 
of these patients. The administration of vasoactive drugs 
(terlipressin, noradrenaline and midodrine plus octreotide) 
in combination with albumin is currently considered the 
treatment of choice. In this regard, terlipressin significantly 
improves reversal of HRS compared to placebo.
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